Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 3/20 | 0.49 |
| ▸ | F3 | P13726 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490050 | 1.00 | ALDH1A1 (0.52) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL1551778 | 0.98 | ALDH1A1 (0.54) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL1551776 | 0.98 | ALDH1A1 (0.54) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL21626134 | 0.95 | ALDH1A1 (0.58) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL8985903 | 0.95 | ALDH1A1 (0.58) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL23294916 | 0.95 | ALDH1A1 (0.58) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL16503992 | 0.93 | ALDH1A1 (0.50) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL14890072 | 0.90 | FAAH (0.53) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL14889921 | 0.90 | FAAH (0.53) | ALDH1A1ALOX15KDM4ELMNATSHR | |
| SCHEMBL14890074 | 0.90 | FAAH (0.53) | ALDH1A1ALOX15KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| EP-3757090-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2024-06-12 | — | — | EP | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-08 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-1781593-A4 | CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS INC (CA) | 2009-04-22 | — | — | EP | disclosed |
| EP-1781593-A2 | CATIONIC LIPIDS AND METHODS OF USE | Protiva Biotherapeutics Inc. (CA) | 2007-05-09 | — | — | EP | disclosed |
| EP-1766035-A1 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2007-03-28 | — | — | EP | disclosed |
| US-20060083780-A1 | Cationic lipids and methods of use | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-04-20 | — | — | US | disclosed |
| US-20060008910-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTIES, INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| WO-2005121348-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005120152-A2 | CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | ALDH1A1 2161/4885ALOX15 1531/4885KDM4E 2406/4885 |
| US-20060008910-A1 | Lipid encapsulated interfering RNA | NPC1L1, LIPA, SYNCRIP | ALDH1A1 3950/4885ALOX15 489/4885KDM4E 3011/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885ALOX15 1985/4885KDM4E 3751/4885 |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, SGMS1, PHOSPHO1 | ALDH1A1 4245/4885ALOX15 359/4885KDM4E 2940/4885 |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885ALOX15 546/4885KDM4E 4752/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | ALDH1A1 2161/4885ALOX15 1531/4885KDM4E 2406/4885 |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | ALDH1A1 2999/4885ALOX15 242/4885KDM4E 1867/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885ALOX15 1985/4885KDM4E 3751/4885 |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | ALDH1A1 2999/4885ALOX15 242/4885KDM4E 1867/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ALDH1A1 1878/4885ALOX15 1398/4885KDM4E 2173/4885 |
| US-20060083780-A1 | Cationic lipids and methods of use | LIPA, CETP, PHOSPHO1 | ALDH1A1 4811/4885ALOX15 393/4885KDM4E 4365/4885 |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885ALOX15 546/4885KDM4E 4752/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ALDH1A1 1878/4885ALOX15 1398/4885KDM4E 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.